Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,161
  • Shares Outstanding, K 8,924
  • Annual Sales, $ 3,310 K
  • Annual Income, $ -8,240 K
  • EBIT $ -9 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.45
  • Price/Sales 9.22
  • Price/Cash Flow N/A
  • Price/Book 4.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.13 +7.80%
on 11/27/24
5.95 -43.36%
on 12/17/24
+0.11 (+3.37%)
since 11/26/24
3-Month
2.44 +38.25%
on 10/10/24
5.95 -43.36%
on 12/17/24
+0.62 (+22.55%)
since 09/26/24
52-Week
2.44 +38.25%
on 10/10/24
6.16 -45.26%
on 12/29/23
-0.74 (-18.00%)
since 12/26/23

Most Recent Stories

More News
Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment

Marker Therapeutics secures $16.1 million through private placement to advance MT-601 clinical trials for lymphoma treatment.Quiver AI SummaryMarker Therapeutics, Inc. announced the completion of a $16.1...

MRKR : 3.37 (-0.30%)
Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients

The APOLLO study reports positive outcomes for MT-601 in relapsed lymphoma, showing high response rates and good tolerance.Quiver AI SummaryMarker Therapeutics, Inc. provided an update on its Phase 1 APOLLO...

MRKR : 3.37 (-0.30%)
Marker Therapeutics Announces $16.1 Million Private Placement

MRKR : 3.37 (-0.30%)
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

MRKR : 3.37 (-0.30%)
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

MRKR : 3.37 (-0.30%)
Marker Therapeutics, Inc. CEO Juan Vera to Present at Ladenburg Thalmann Virtual Symposium on December 12, 2024

Marker Therapeutics CEO Juan Vera will present at the Ladenburg Thalmann Virtual Oncology Symposium on December 12, 2024.Quiver AI SummaryMarker Therapeutics, Inc., a Houston-based clinical-stage immuno-oncology...

MRKR : 3.37 (-0.30%)
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

MRKR : 3.37 (-0.30%)
Marker Therapeutics, Inc. CEO Juan Vera to Present at Citizens JMP Hematology and Oncology Summit on December 2, 2024

Marker Therapeutics CEO Juan Vera will present company updates at the Citizens JMP Hematology and Oncology Summit on December 2, 2024.Quiver AI SummaryMarker Therapeutics, Inc. announced that its President...

MRKR : 3.37 (-0.30%)
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

MRKR : 3.37 (-0.30%)
Marker Therapeutics, Inc. Reports Third Quarter 2024 Financial Results and Progress on Clinical Trials

Marker Therapeutics reports Q3 2024 financial results, highlighting progress in clinical trials and $4 million in NIH grants.Quiver AI SummaryMarker Therapeutics, Inc. announced corporate updates and financial...

MRKR : 3.37 (-0.30%)

Business Summary

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T...

See More

Key Turning Points

3rd Resistance Point 3.77
2nd Resistance Point 3.66
1st Resistance Point 3.52
Last Price 3.37
1st Support Level 3.26
2nd Support Level 3.15
3rd Support Level 3.01

See More

52-Week High 6.16
Fibonacci 61.8% 4.74
Fibonacci 50% 4.30
Fibonacci 38.2% 3.86
Last Price 3.37
52-Week Low 2.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar